We invite everyone to participate in the survey “Understanding Preferences for Tuberculosis Diagnosis at Healthcare Facilities to Support the Development of New Tests.” Please note that the survey is available only in English and will take no more than 15 minutes to complete. The goal of the survey is to collect opinions from healthcare professionals, policymakers, researchers, and affected communities
October 25-28, 2023, Washington, D.C. – Sixteen representatives of communities affected by tuberculosis (TB), with experience in TB during pregnancy, gathered to reach a consensus on the inclusion of pregnant and breastfeeding women and other individuals in TB treatment and vaccine research.
Emcure was founded in 1983 in India. In addition to ARVs, the company produces a wide range of other drug products. In addition to finished products, the company produces active pharmaceutical ingredients.
We are glad to present minutes of ECAT meeting with with Hetero, Mylan, Emcure and TB-Alliance which took place in Armenia in October 2019.
Emcure was founded in 1983 in India. In addition to ARVs, the company produces a wide range of other drug products. In addition to finished products, the company produces active pharmaceutical ingredients, which means that the company has a full production cycle.
One of the largest manufacturers of ARVs and API in the world.
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs. Hetero’s business includes APIs, generics, biosimilars, custom pharmaceutical services, and branded generics.
TB-Alliance is a non-profit organization founded in 2000 to develop and market new, more effective drugs for the treatment of tuberculosis with a shorter treatment duration. It is a partnership that develops drugs located in New York and South Africa. TB-Alliance works in close partnership with pharmaceutical companies, research institutes and community around the world.
Minutes of the meeting of ECAT and HIV and hepatitis drugs manufacturers are available now. The meeting took place on April, 24-26th, 2019, in St Petersburg, Russia, gathering together more than 30 HIV, hepatitis and TB access to treatment activists from EECA region.
The meeting minutes with Gilead Sciences (including the meetings between EECA CAB and the company).
